Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Molecular dynamics (MD) simulations have become increasingly useful in the modern drug
development process. In this review, we give a broad overview of the current application …

The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter-and intra-
cellular communication, which regulates fundamental cell functions such as growth, survival …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

KRAS mutations are among the most common genetic alterations in lung, colorectal, and
pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit …

Abstract RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the
most frequently mutated genes in cancer, with common driver mutations occurring at codons …

Mutational activation of KRAS promotes the initiation and progression of cancers, especially
in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific …

One of the most common drivers in human cancer is the mutant KRAS protein. Not so long
ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however …

Neurofibromin is a large and multifunctional protein encoded by the tumor suppressor gene
NF1, mutations of which cause the tumor predisposition syndrome neurofibromatosis type 1 …